$LLY (Eli Lilly and Company)

$LLY {{ '2015-07-23T15:09:24+0000' | timeago}} • Webcast

$LLY 2Q15 Call: With tangible results from LLY’s innovation-based strategy, it aims to drive revenue growth & expand margins throughout the balance of this decade. LLY will sharpen its focus on areas where it is best positioned to compete and win, and will continue to find ways to increase productivity & do the work of pharmaceutical R&D better.

$LLY {{ '2017-10-18T18:15:06+0000' | timeago}} • Announcement

$LLY inks a deal with Germany-based CureVac to develop and market up to 5 cancer vaccines. Lilly would pay CureVac $50MM as upfront fee and make an equity investment of EUR45MM. If successful, CureVac would receive more than $1.7Bil as milestone payment. Subject to the closing, Lilly expects to incur a charge of $0.03 per share to its earnings.

$LLY {{ '2017-10-16T19:27:03+0000' | timeago}} • Announcement

The BoD of $LLY declared a dividend for 4Q17 of $0.52 per share, payable on Dec. 8, 2017 to shareholders as of Nov. 15, 2017.

$LLY {{ '2017-10-12T14:50:24+0000' | timeago}} • Announcement

FDA grants priority review for $LLY's breast cancer drug Verzenio, which was approved by the agency on Sept. 28. 2017. Now, FDA will speed up the review and will take action within eight months.  On Oct. 10, 2017, Lilly announced that Verzenio failed in the Phase 3 study for treating advanced lung cancer.

$MCK {{ '2017-10-11T18:31:37+0000' | timeago}} • Announcement

Biologics, a $MCK Specialty Health oncology pharmacy services company, has been selected by $LLY to be in the limited distribution network for Verzenio (abemaciclib), $LLY's first oral oncolytic indicated for metastatic breast cancer. Verzenio obstructs growth of cancer cells by specifically blocking cyclin-dependent kinases, CDK4 and CDK6.

$LLY {{ '2017-10-10T13:44:54+0000' | timeago}} • Announcement

$LLY's advanced lung cancer treatment drug Verzenio flunks in meeting the end goal of overall survival among the 453 patients in the Phase 3 JUNIPER trial study. The most common adverse events experienced by these patients were diarrhea, fatigue, decreased appetite, and nausea. Last month, FDA approved Verzenio for the treatment of breast cancer.

$LLY {{ '2017-10-06T18:13:20+0000' | timeago}} • Announcement

The U.S. Patent and Trademark Office (PTO) ruled in favor of $LLY for its cancer drug Alimta. The review was initiated by Neptune Generics and Sandoz Inc and PTO concluded that claims of the Alimta vitamin regimen patent are valid. If the patent is upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022.

$LLY {{ '2017-10-05T17:01:58+0000' | timeago}} • Announcement

$LLY announced that its breast cancer drug Verzenio (abemaciclib) will be available in U.S. by mid Oct.-2017. On Sept. 28, 2017, FDA approved Lilly's Verzenio.

$LLY {{ '2017-10-04T18:08:34+0000' | timeago}} • Announcement

Humalog Junior KwikPen, a prefilled and disposable half-unit insulin pen from $LLY, will be available now in U.S. for treating type 1 and type 2 diabetes. In June 2017, Humalog Junior KwikPen was approved by the FDA and it is expected to get the EU's approval later in 2017.

$LLY {{ '2017-09-29T12:44:44+0000' | timeago}} • Announcement

$LLY announced about the retirements of two senior leaders. Maria Crowe, President of manufacturing operations will retire in Dec. 2017 and Jan Lundberg, EVP for science & technology and President of Lilly Research Labs, will retire at the end of May 2018. In June, Lilly announced that its current CFO Derica Rice would retire at 2017-end.

$LLY {{ '2017-09-29T12:33:31+0000' | timeago}} • Announcement

$LLY announces senior leadership changes for finance, R&D and manufacturing, effective 2018. This includes the promotion of Josh Smiley as CFO and Dan Skovronsky as SVP for science & technology and president of Lilly Research Labs. Also, Myles O'Neill will take over the lead role in manufacturing and CIO Aarti Shah elevated as an executive officer.

$LLY {{ '2017-09-28T21:06:48+0000' | timeago}} • Announcement

FDA approves $LLY's breast cancer drug Verzenio (abemaciclib), which will compete with $PFE's Ibrance and $NVS' Kisqali drugs. Verzenio works by blocking certain molecules involved in promoting the growth of cancer cells. The National Cancer Institute estimated that approximately 252,710 women will be diagnosed with breast cancer this year.

$LLY {{ '2017-09-25T13:18:33+0000' | timeago}} • Announcement

Geisinger and Boehringer Ingelheim, on behalf of its partnership with $LLY, announced that they will create a model to predict the three major outcomes associated with type 2 diabetes. The new model will allow to predict the complications from cardiovascular death, kidney failure and hospitalization for heart failure.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$LLY {{ '2017-09-12T14:09:14+0000' | timeago}} • Announcement

$LLY announced that Jardiance tablets reduced the risk of cardiovascular death in people with Type 2 diabetes and established cardiovascular disease independent of blood sugar control. Jardiance also reduced the risk of cardiovascular death compared to placebo regardless of background Metformin or Sulfonylurea use.

$LLY {{ '2017-09-11T15:56:35+0000' | timeago}} • Announcement

$LLY  to present data for Olumiant (baricitinib) for the treatment of moderate-to-severe atopic dermatitis at the annual European Academy of Dermatology and Venereology Congress (EADV) in Geneva during Sept 13-17, 2017. Lilly is also set to present data for its psoriasis drug Taltz in EADV.

$LLY {{ '2017-09-11T15:50:35+0000' | timeago}} • Announcement

$LLY presented data from Phase 3 RANGE study of Cyramza (ramucirumab) for the treatment of urothelial cancer. Lilly added that Cyramza significantly increased progression-free survival (PFS) by almost 25% compared with placebo. RANGE overall survival (OS) data are immature and final OS results are currently expected in mid-2018.

$LLY {{ '2017-09-11T15:30:38+0000' | timeago}} • Announcement

$LLY stated that its migraine treatment drug Lasmiditan reduces pain. Lilly presented the data related to this study in the 18th Congress of the International Headache Society (IHC) in Vancouver. The company plans to submit a NDA for Lasmiditan to FDA in 2H18.

$LLY {{ '2017-09-08T15:16:54+0000' | timeago}} • Announcement

$LLY reported that its migraine treatment drug Galcanezumab had positive long-term safety results from a 12-month, open-label study. The detailed results will be presented at a conference in Vancouver on Sept 8, 2017. Lilly plans to submit a Biologics License Application (BLA) to FDA for Galcanezumab in 2H17.

$LLY {{ '2017-09-07T17:35:51+0000' | timeago}} • Announcement

As part of the streamlining initiatives, $LLY expects to eliminate the majority of the employees through a U.S. voluntary early retirement program. Lilly also plans to close certain sites, including R&D offices in Bridgewater, New Jersey and Shanghai, China. The company plans to invest in new medicines and drive growth.

$LLY {{ '2017-09-07T17:22:37+0000' | timeago}} • Announcement

$LLY to cut 3,500 jobs globally. The drugmaker expects annualized savings of $500MM beginning in 2018. Lilly expects to incur charges of approx $1.2Bil pre-tax or $0.80 per share after-tax. As a result of the streamlining initiatives, 2017 GAAP EPS is expected to be reduced by the amount of the charges and non-GAAP EPS outlook is unchanged.

Recent Transcripts

ABT (Abbott Laboratories)
Wednesday, October 18 2017 - 1:00pm
ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
ZGNX (Zogenix, Inc.)
Tuesday, August 8 2017 - 8:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 3:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
FGEN (FibroGen, Inc.)
Monday, August 7 2017 - 9:00pm
XNCR (Xencor, Inc.)
Monday, August 7 2017 - 8:30pm
ARQL (ArQule Inc.)
Friday, August 4 2017 - 1:00pm
AET (Aetna Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
EXEL (Exelixis, Inc.)
Wednesday, August 2 2017 - 9:00pm
ZIOP (ZIOPHARM Oncology, Inc.)
Monday, July 31 2017 - 8:30pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
IMGN (ImmunoGen, Inc.)
Friday, July 28 2017 - 12:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm

AlphaGraphics you may like